Italia markets open in 30 minutes

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,98-0,17 (-2,76%)
Alla chiusura: 04:00PM EDT
6,21 +0,23 (+3,85%)
Dopo ore: 06:08PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,15
Aperto6,07
Denaro5,85 x 100
Lettera6,08 x 100
Min-Max giorno5,85 - 6,17
Intervallo di 52 settimane5,85 - 18,65
Volume199.682
Media Volume105.840
Capitalizzazione109,769M
Beta (5 anni mensile)0,44
Rapporto PE (ttm)N/D
EPS (ttm)-1,41
Prossima data utili07 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A22,00
  • GlobeNewswire

    Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

    Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows: Date Tuesday, September

  • GlobeNewswire

    Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

    Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AA

  • GlobeNewswire

    Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

    Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”). The study is designed to evaluate the safety, tolerability